BSA
NUVA

Braun Stacey Associates’s NuVasive, Inc. NUVA Stock Holding History

Braun Stacey Associates’s Portfolio NUVA Stock Details NUVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-186,567
Closed -$9.17M – 145
2022
Q2 		$9.17M Buy
+186,567
New +$10M 0.52% 82

Other funds holding NUVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCM
Channing Capital Management Chicago, Illinois $4.34B AUM 37.08% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return

Braun Stacey Associates's NUVA Position: Q3 2022 in Review

Braun Stacey Associates sold out of NuVasive, Inc. (NUVA) in Q3 2022, closing a stake of 186,567 shares — an estimated $9.17M sold.

Braun Stacey Associates first reported a position in NUVA in Q2 2022 and held it in 1 quarter. The position peaked at $9.17M in Q2 2022. 232 funds tracked by Wall St. Rank hold NUVA as of Q3 2022.

  • Braun Stacey Associates reported no remaining NuVasive, Inc. position as of Q3 2022 after selling out during the quarter.
  • Braun Stacey Associates sold 186,567 NuVasive, Inc. shares in Q3 2022, an estimated $9.17M.
  • Braun Stacey Associates first reported a position in NuVasive, Inc. in Q2 2022 and held it in 1 quarter.
  • Braun Stacey Associates's NuVasive, Inc. position peaked at $9.17M in Q2 2022.
  • 232 funds tracked by Wall St. Rank held NuVasive, Inc. as of Q3 2022.

Based on Braun Stacey Associates's 13F filing for Q3 2022, filed 8 Nov 2022.